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ABSTRACT 
 Prescription drug abuse is an intentional misuse of a prescribed drug for recreational or 
other purposes that was not intended by the prescriber of the drug. Since 2012, fatalities from 
opioid overdoses have risen to approximately 17,000 per year in the United States. It is important 
for healthcare providers to follow a standardized guideline with patients receiving controlled 
substances, such as opioids, in order to prevent abuse. Within this project, a chronic pain 
management protocol was created, implemented, and evaluated in a selected critical access 
hospital’s emergency department and two rural health clinics.  The protocol addressed the use of 
an online prescription drug monitoring program (PDMP) to identify patients who have a history 
of obtaining multiple controlled substance prescriptions and using multiple pharmacies to fill 
these prescriptions. In addition to using a PDMP, providers are educated in identifying risk 
factors of opioid use in their patients by using an evidence-based risk assessment tool. Opioid 
abuse prevention strategies and best practices for opioids prescribing are within the protocol. 
Strategies include pain treatment contracts and a stepwise approach to prescribing based on the 
patient’s report of pain, with opioids as the last resort. Other methods include urine drug 
screening, a nonjudgmental attitude from the provider towards the patient regarding abuse, and 
motivational interviewing methods to assist patients to stop abuse. Emphasis on other 
nonpharmacological methods are included, such as: physical therapy, cognitive behavioral 
therapy, counseling, yoga, biofeedback, and guided imagery. Evaluation of this protocol includes 
pre- and post-implementation surveys with the project stakeholders, including administrators and 
providers within the project hospital and clinics. 
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CHAPTER ONE. INTRODUCTION OF PRESCRIPTION DRUG ABUSE 
 Prescription drug abuse is identified as the intentional misuse of a prescribed drug for 
recreational or other purposes that was not intended by the prescriber of the drug (National 
Institute on Drug Abuse [NIDA], 2011). Statistics regarding prescription drug abuse are 
astounding and reveal the severity of the problem. The National Institute on Drug Abuse 
comments that: “Prescription drug abuse remains a significant problem in the United States” 
(NIDA, 2011). In 2010, approximately seven million people (2.7% of the US population) in the 
United States were illegally using prescription drugs (NIDA, 2011). These statistics represent a 
significant problem of prescription drug abuse in the US.  Not only are prescription drugs a 
significant problem in the United States, but North Dakota has also been affected with problems 
with prescription drug abuse. According to the North Dakota Office of the Attorney General 
(2014), 17.6% of North Dakota high school students admit to taking a controlled substance, such 
as OxyContin, Percocet, or Vicodin, without a prescription from a provider at least once. The 
statistic is equivalent to the national rate (North Dakota Office of the Attorney General, 2014). 
The 17.6% of North Dakota high school students who admit to prescription drug abuse illustrates 
an ongoing problem with prescription drug abuse in North Dakota. There has not been further 
research by the North Dakota Office of the Attorney General to include the prevalence of 
prescription drug abuse among North Dakota young adults and adult populations. 
 Therefore, the purpose of this project is to identify those populations in North Dakota 
who are at risk for prescription drug abuse, as well as seek to educate health care providers 
regarding best practices when prescribing controlled substances and preventing prescription drug 
abuse.  The project goals were achieved through providing tools with which to identify those 
high-risk populations, in order to help prevent access to prescription drugs by the identified high-
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risk populations. Furthermore, this project compared prescription drug abuse prevention methods 
used by rural primary health care providers in two clinics and one critical access hospital’s 
emergency department in northwestern North Dakota. This project evaluated how the 
development and utilization of pain management protocols can help prescribers deter and prevent 
prescription drug abuse. This project further explored each prescriber’s biases and treatment 
methods used for the patient. By considering common treatment methods between prescribers, a 
common ground was identified in order to centralize communication between prescribers to help 
decrease the incidence of prescription drug abuse in a northwestern North Dakota rural health 
clinic and a critical access hospital’s emergency department. 
Significance of Prescription Drug Abuse 
Opioids are frequently used for a recreational purpose instead of original medical 
purpose, such as pain management (Green et al., 2011). Opioid use is now associated with grave 
concern in public health because the inappropriate use of opioids is responsible for addiction, 
fatal overdoses, and mixing with other drugs to make a fatal combination (Green et al., 2011). 
Benzodiazepines, stimulants, hypnotics, and opioids are classes of drugs that are the most 
addictive (Julien, Advokat, & Comaty, 2011).  There are certain classes of medications that are 
more commonly abused than other classes. The NIDA (2011) reports these classes and the 
approximate number of people abusing them are: pain relievers - 5.1 million, tranquilizers - 2.2 
million, stimulants - 1.1 million, and sedatives – 0.4 million. 
Deaths due to prescription drug abuse exceeded motor vehicle crashes in 2009 as the 
number one cause of accidental death in the United States (Green et al., 2011). Prescription drug 
abuse has become one of the most serious substance abuse problems in the US, possibly because 
they are easily accessible (Green et al., 2011). The prevalence of prescription drug abuse has 
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reached epidemic proportions within the past two decades (Carlson et al., 2014; Kelly, Rendina, 
Vuolo, Wells, & Parsons, 2015; and McHugh, Nielsen, & Weiss, 2015).  
In addition to statistics regarding prescription drug abuse, alcohol use with either illicit or 
prescription drugs is a significant problem. The dangers of combining opioids and alcohol are 
particularly dangerous due to both substances causing respiratory depression, which can lead to 
death (Phillips, 2013; Crist & Berrettini, 2014). According to Jung (2010), the incidence of 
people who abuse alcohol are more likely to abuse drugs as well. According to Julien et al. 
(2011), combinations of alcohol and benzodiazepines or other sedatives can result in 
significantly impaired coordination required to operate a motor vehicle, or inability to conduct 
other activities requiring alertness. Based on the above, it is important for providers to assess a 
patient’s alcohol or illicit drug use, abuse, or addiction as part of the pain management protocol. 
Chronic Pain   
            There are approximately one hundred million people in the United States that suffer from 
chronic pain (Katzman, Comerce, Landen, Loring, et al., 2014). Of these one hundred million 
people, it is estimated that “thirty-five million Americans (13.7%) adults age 12 years and older 
had used a pain reliever non-medically at least once in their lifetime” (Katzman et al., 2014, p. 
1356). An estimated 15.7 million Americans admit to using prescription drugs for recreational 
purposes (Beauchamp et al., 2014). A troubling consequence of the abuse is the high number of 
accidental overdoses that result (Beauchamp, Winstanley, Ryan, & Lyons, 2014). Approximately 
46 Americans die daily as a result of an accidental opioid overdose (Beauchamp et al., 2014). 
The above high statistics indicate that prescription drug abuse is now in epidemic proportions in 
the United States healthcare system (McHugh et al., 2015). Green, Black, Serrano, Budman, and 
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Butler (2011) report that controlled substances such as opioids now exceed marijuana as the 
substance that most first-time drug users become addicted to. 
Problem Statement or Purpose 
 The prevalence of prescription drug abuse in our healthcare system has led many 
providers to take various measures in the clinical setting to help keep it under control. These 
measures include treatment agreements, random urine or serum drug screens, communication 
between providers, communication between providers and pharmacists, and communication via a 
prescription drug monitoring program. Many primary care providers choose not to prescribe 
addictive medications to their patients. Some providers focus primarily on eradicating their 
patient’s pain or anxiety, and their prescriptive practices do not account for addictive behaviors 
of patients. 
 Furthermore, pain management education is essential for patients with and at risk for 
addiction issues. First, the addicted patient needs to be identified. Within the pain management 
protocol developed during this project, the tool included to help identify a patient with a high 
risk of addiction or an actual addiction is the Opioid Risk Tool. The Opioid Risk Tool was 
developed in 2010 by Dr. Lynn Webster and is used in many pain management clinics. Many 
times the best option to prevent addiction is not to prescribe an opioid, particularly for an 
individual at high risk for opioid abuse and dependence (Matthias et al., 2013). Alternative 
methods of pain management, such as physical therapy, biofeedback, psychotherapy, or yoga are 
effective. Frequent assessments of skin need to be completed at every visit, paying close 
attention to any skin ulcers that may be present due to intravenous drug use or “skin popping” 
(Canales, Gerhard, & Younce, 2015).  
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 Deaths from opioid use, whether intentional as suicide or unintentional as an overdose, 
have been dramatically increasing in the US within the past two decades; unfortunately, the 
opioids were obtained from a prescriber in many cases (Haegerich, Paulozzi, Manns, & Jones, 
2014). Since this is such a risk, prescribers need to be diligent with follow-up on their patients to 
assess that they are taking their prescriptions exactly as directed.  
 Prescribing practices between healthcare providers have a wide variance and there is a 
need for guidelines for improvement on both the provider’s and the patient’s accountability. 
Many states are monitoring providers’ prescribing statistics through their prescription drug 
monitoring programs, ranging from “pill mills”, which is considered inappropriate prescribing to 
minimal prescribing (Haegerich et al., 2014). Health insurance companies, such as Medicaid, 
Medicare, and private in conjunction with “pharmacy benefit managers”, or PBMs, create alerts 
for providers to become aware of evidence-based prescribing practices and if any overlapping 
activity is occurring with their patient’s prescriptions with other providers (Haegerich et al., 
2014). These alerts are helpful to prescribers, but there is a need for pain management protocols 
in all individual clinics so each clinic may monitor providers’ prescribing practices internally. 
Additionally, not all patients have health insurance that can monitor prescribing practices. 
 While overuse and abuse of controlled prescription medications is of paramount concern, 
many patients take less of their medications in order to avoid addiction and do not disclose such 
to their provider (Daughton & Ruhoy, 2013). As a result, the provider continues to prescribe the 
same quantity of the prescription, which creates a stockpile of medications (Daughton & Ruhoy, 
2013). This stockpile of medications thus leads to more problems; such as unnecessary waste, 
unnecessary costs, possible diversion, and unintended overdoses either by children having access 
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to the medications, or someone who does not know what the medication is for (Daughton& 
Ruhoy, 2013). 
Project Description with Purpose and Objectives 
 This project included a development of a pain management protocol within a critical 
access hospital’s emergency department in North Dakota and two affiliated rural primary care 
clinics. A pre- and post-implementation survey was distributed to each participating 
administrator and provider. The data from these surveys were analyzed with comparisons to 
determine the effectiveness of the protocol. Each licensed staff member [registered nurses (RN) 
and licensed practical nurses (LPN)] was individually taught how to recognize risk factors of 
prescription drug abuse in patients. Each RN and LPN gained access to PDMP as a delegate 
under the supervision of the medical chief of staff in order to research each patient that is 
prescribed opioids in the critical access hospital’s emergency department and two rural 
healthcare clinics. The hospital and clinics are where this student was employed. 
Congruence of the Project to the Organization’s Strategic Plans/Goals 
 The primary stakeholders identified in this project are employees of the two rural clinics 
and critical access hospital’s emergency department in northwestern North Dakota, including 
four medical doctors, one doctor of osteopathy, and three family nurse practitioners. These 
employees were active participants in the planning, creating, implementation, and evaluation of 
the pain management protocol in these facilities. 
 The mission statement for the hospital and clinics “is to provide comprehensive and 
compassionate health care for individuals and families in cooperation with the area medical 
community” (Anonymous, n.d.). The content of the developed and implemented pain 
management protocol maintained compassion and empathy for the patient in order to remain 
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congruent with the organization’s mission statement. In addition to compassion and empathy to 
the patient, the pain management protocol contained the most recent comprehensive healthcare 
strategies to provide pain management as well as prevention of prescription drug abuse. 
Project Objectives 
 The project has the following objectives: 
 Objective 1: Develop and implement a pain management protocol in a rural North Dakota 
primary care clinic and critical access hospital’s emergency department. 
 Objective 2: Improve, increase, and expand providers’ knowledge about safe opioid 
prescribing practices in order to improve patient monitoring for those receiving opioid 
therapy for chronic pain management. 
 Objective 3: Promote utilization and sustainability of the pain management protocol 
through integration of the protocol into daily provider and staff operations in selected 
clinics within four months from project implementation to evaluation. 
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CHAPTER TWO. LITERATURE REVIEW 
 There are many different methods that providers can use to monitor their patients on 
opioids and other controlled substances in order to prevent prescription drug abuse. Providers 
need to be able to recognize some of these abuse risk factors via assessment tools. Primary care 
providers especially need to be assessing their patients with several different methods; such as 
using the prescription drug monitoring program, urine drug screening, and treatment agreements. 
Sometimes providers need to be creative in working with their patients in initiating change as in 
motivational interviewing. Approaches such as providers involving themselves with continuing 
education about opioid pharmacology and prescribing opioids have been found to be helpful. It 
has been found helpful for providers being consistent with their prescribing methods, use of 
patient monitoring techniques to prevent prescription drug abuse, and use of pain management 
protocols whenever available. 
 The North Dakota Prescription Drug Monitoring Program, now called PDMP is a tool 
that prescribers can utilize to assess their patients’ activity on receiving controlled substance 
prescriptions from other providers and the pharmacies that they have had their prescriptions 
filled. Kathy Zahn, director of the North Dakota PDMP, reports that as of fourth quarter of 2014, 
17.9% of North Dakota physicians (e.g., medical doctors and doctors of osteopathy) and 36.4% 
of North Dakota advanced practice providers (e.g., nurse practitioners and physician assistants) 
accessed and utilized the monitoring system (telephone communication, 3/12/15). 
 It is unknown why the above statistics of PDMP utilization are low among providers. The 
top reasons are that the providers do not have access to the PDMP for various reasons; providers 
are unaware of the PDMP existence; and providers do not have the time to access the PDMP 
(Perrone, DeRoos, & Nelson, 2012). Many providers identify barriers to using the PDMP as 
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time-consuming from entering the patient’s information to the final report, as well as inconsistent 
prescription and pharmacy information between states (Hildebran et al., 2014).  
 However, the benefits of PDMP utilization outweigh the barriers in that providers can 
become more aware of their patients’ controlled substance prescription activity by receiving 
additional prescriptions from other providers, and using multiple pharmacies (Green, Mann, 
Bowman, Zaller, Soto, Gadea, Cordy, et al., 2012). In addition to monitoring, printed PDMP 
reports that are discussed between a provider and a patient can become an excellent teaching tool 
to make the patient aware of their own addiction (Green et al., 2012). Based on the above 
information, PDMP utilization by providers has the potential for many opportunities for 
improvement in controlled substance prescribing and prevention of prescription drug abuse. 
Medications with Potential for Abuse 
Opioids 
 The mechanism of action of opioids involves three types of receptors in the central 
nervous system and in the peripheral nervous system; which are mu, kappa, and delta (Julien et 
al., 2011). Mu receptors have the most significant effects in the brain, especially the thalamus, 
brain stem, and spinal cord (Julien et al., 2011). The mu receptors have the strongest properties 
for addiction, are the most effective for pain control, and are the most dangerous because of the 
respiratory depressive effect on the brain stem (Julien et al., 2011). The kappa receptors have 
minimal pain control properties and minimal to no properties for addiction (Julien et al., 2011). 
Delta receptors also have minimal to no properties for addiction and minimal pain control 
properties (Julien et al., 2011). When drugs that affect the dopamine pathways such as opioids 
are abused, it causes a pleasurable surge in the dopamine pathways in the brain, and with 
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repeated use, can lead to addiction (NIDA, 2012). Opioids such as OxyContin stimulate the same 
receptors as heroin (NIDA, 2012).  
 The physiological effects of opioids are processed in the brain; the thalamus, the 
periaqueductal gray matter where the serotonin pathways, enkephalin pathways, and 
noradrenaline pathways are located (Julien et al., 2011). In these areas, the pathways are 
stimulated by the opioids and inhibit pain transmission (Julien et al., 2011). With the case of 
chronic pain, the pathways are damaged, thus limiting the pain transmission inhibition, which is 
called neuroadaptation (Julien et al., 2011). For this reason, opioids are a poor choice for chronic 
pain maintenance (Julien et al., 2011). 
 The psychological effect of opioids includes euphoria that is caused from the release of 
endorphins from the dopamine pathways (Julien et al., 2011). Many people who abuse opioids 
do it for the pleasurable effects and develop a psychological obsession to continue to abuse for 
the relief of emotional pain regardless of the consequences (Julien et al., 2011). Julien et al. 
(2011) also discuss the following: “Morphine produces a pleasant euphoric state, which includes 
a strong feeling of contentment, well-being, and lack of concern” (p. 332). The feelings that 
result from habitual morphine use “is part of the affective, or reinforcing, response to the drug” 
(Julien et al., 2011, p. 332).  
Opioids produce sedation and anxiolysis due to slowing down cognitive processes, 
although the patient can easily be awakened, unlike central nervous system depressants such as 
alcohol (Julien et al., 2011). A dangerous effect of opioids is respiratory depression ranging from 
sleep apnea to respiratory cessation due to “decreasing the respiratory center’s sensitivity to 
higher levels of carbon dioxide in the blood” (Julien et al., 2011, p. 334). Julien et al. (2011) also 
state that, “Respiratory depression is the single most important acute side effect of morphine and 
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is the cause of death from acute opioid overdosage [sic]” (p. 334).  A unique characteristic of 
opioid use is pupillary constriction, especially from “mu and kappa agonists” (Julien et al., p. 
334).  Julien et al. (2011) also state that “pupillary constriction in the presence of analgesia is 
characteristic of opioid ingestion” (p. 334). Nausea and vomiting is caused by stimulation of the 
“chemoreceptor trigger zone in the medulla” (Julien et al., p. 334). Constipation is a common 
gastrointestinal effect from opioid use due to decreased gastrointestinal motility and increased 
fluid absorption from fecal material, creating hardened stools (Julien et al., 2011).  
Endocrine effects from opioid use include irregular menses and decreased fertility in 
women, and decreased sex drive and “hypogonadism” in men (Julien et al., 2011, p. 335). Opioid 
tolerance can develop quickly due to “glutaminergic receptors”, which “regulates the mu 
receptor messenger (m) ribonucleic acid (RNA)”, and creates “tolerance” with the opioid always 
being at the receptors (Julien et al., 2011, p. 336). Problems with opioid tolerance occur when the 
opioid is used on a regular basis, due to loss of efficacy from the original dose (Julien et al., 
2011). As a result, the patient will complain of more pain and the dosage will have to be 
increased in order for the patient to achieve the same quality of pain control as they had when 
they first began using the opioid. Julien et al. (2011) commented, “The use of all mu agonist 
opioids is severely limited because of the development of tolerance, the presence of 
uncomfortable side effects, and the potential for compulsive abuse” (p. 335).  
 Acute withdrawal symptoms of opioids include, “pain and irritability, hyperventilation, 
dysphoria and depression, restlessness and insomnia, fearfulness and hostility, increased blood 
pressure, diarrhea, pupillary dilation, hyperthermia, lacrimation, runny nose, spontaneous 
ejaculation, and chilliness and ‘gooseflesh’” (Julien et al., 2011, p. 337). These symptoms are 
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extremely unpleasant to the person experiencing them, but they are not potentially fatal (Julien et 
al., 2011). 
 Protracted abstinence syndrome is the time frame after acute withdrawal symptoms from 
opioids up to six months after cessation of opioid use (Julien et al., 2011; Smith & Aston-Jones, 
2014; Stinus, Cador, & Caille, 2012). The hallmark symptoms of protracted abstinence syndrome 
include depression, dramatic responses to stress, craving the drug of choice, low self-image, and 
other mental health problems (Julien et al., 2011). During the time frame of protracted abstinence 
syndrome, there are co-occurring or dual diagnoses that can be identified in the patient; such as, 
“affective and personality disorders” with “antisocial personality disorders and major 
depression” being the most common co-occurring disorders (Julien et al., 2011, p. 338). 
Benzodiazepines 
 Julien et al. (2011) state, “All benzodiazepines are termed pure GABA agonists because 
they faithfully facilitate GABA binding at GABA receptors” (p. 250). Benzodiazepines are 
appropriate for short-term anxiety use, but inappropriate for treatment of depression or long-term 
anxiety (Julien et al., 2011). They are effective for treatment of insomnia, but with risk of 
addiction (Julien et al., 2011). There are cases of people who develop “paradoxical agitation 
(anxiety, aggression, hostility, and behavioral disinhibition)” while taking benzodiazepines 
(Julien et al., 2011, p. 253). Alcohol combined with benzodiazepines can be especially dangerous 
due to decreased metabolism of both substances, leading to toxicity (Jung, 2010). There have 
been many fatalities due to this combination of substances (Julien et al., 2011). 
 Another common use of benzodiazepines is for anesthesia and conscious sedation for 
surgical procedures (Julien et al., 2011). Midazolam, or Versed, is the best-known short-acting 
benzodiazepine that is used for procedures, mainly for its amnesic effect (Julien et al., 2011). 
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 When a benzodiazepine overdose is suspected in an emergency department, an antidote 
called flumazenil (Romazicon) is given intravenously to reverse the toxic effects of the 
benzodiazepines (Julien et al., 2011). Due to the short half-life of flumazenil, multiple doses may 
have to be given due to the recurrence of the benzodiazepine toxicity (Julien et al., 2011). 
   A working knowledge of drugs with the potential for abuse and mechanism of action of 
those drugs is helpful for providers who have prescriptive authority, and the knowledge can be 
used to further educate patients. Education is extremely important; it can mean life or death to 
many people. An extensive examination of the neurology, pharmacology, and the progression, 
diagnosis, and treatment of an opioid use disorder is not within the scope of this project. 
Assessing Risk Factors for Opioid Abuse 
 There are known characteristics, or risk factors, for a patient to be at high risk for opioid 
abuse. These risk factors can be assessed by providers by using an assessment tool, such as the 
“Current Opioid Misuse Measure (COMM)” questionnaire that was developed by the National 
Institutes of Health and PainEDU@inflexxion.com (Inflexxion, 2008). The patient completes the 
questionnaire and the answers that are provided assists the provider to determine whether the 
patient is at high risk of opioid abuse or not. The questionnaire consists of 17 questions that has 
the patient consider a time frame of the past thirty days. The risk factors that are addressed in the 
questionnaire are the following according to the COMM: Evidence of physiological dependence, 
irrational emotions, non-therapeutic responses to opioids, evidence of psychological dependence, 
frequent use or abuse of healthcare, and frequent requests for early refills of opioids (Inflexxion, 
2008). 
 In addition to the COMM assessment tool, the “Screener and Opioid Assessment for 
Patients with Pain (SOAPP)” was also developed by the National Institutes of Health and 
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PainEDU@inflexxion.com (Inflexxion, 2008). The twenty-four item questionnaire is designed in 
a five-point Likert scale from 0 representing “never” to 4 representing “very often” (Inflexxion, 
2008). The content of the questions addresses the patient’s behavior issues, illicit drug use, 
prescription drug abuse, family history of alcohol or drug abuse, any history of alcohol or drug 
treatment, problems with providers, and legal issues (Inflexxion, 2008). The content of these 
questions indicate the population at risk for opioid abuse. 
 Another risk assessment tool that is used is called the “Opioid Risk Tool” developed by 
Lynn R. Webster, MD in 2010. It addresses gender, family history of substance abuse, personal 
history of substance abuse, age range that is high risk for abuse, any history of sexual abuse, and 
any presence of mental health disorders (Webster, 2010). This assessment tool and the two 
preceding tools can give the provider an idea of the patient’s prescription drug abuse risk factors. 
The tool that was used within this project was the “Opioid Risk Tool”.  
 The Opioid Risk Tool is a good resource for the provider to gather data about opioid 
abuse risk factors, but many patients evade the truth by answering questions dishonestly for fear 
of rejection from the provider (Webster, n.d.). According to Dr. Webster (n.d.), the best methods 
of screening patients for opioid abuse is by observing the behaviors, consulting the prescription 
drug monitoring program which includes patients’ provider and pharmacy activity, and have the 
patient come into the office for frequent visits. Also, it is important to validate the patient’s pain 
and develop a trusting relationship early (Webster, n.d.). The above tools have a high validity 
that assists providers in safe opioid prescribing. 
Prescription Drug Abuse Management in Primary Care 
Within the primary care system, any pain management program involves a multi-pronged 
approach designed to assess risk and minimize abuse of prescription medications. Abusive 
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prescription medication behaviors need to be identified and the provider needs to be able to 
modify abusive behaviors through the use of a treatment agreement or treatment contract. 
  In 2005, the North Dakota Legislative Assembly, in conjunction with the North Dakota 
Board of Pharmacy, implemented a computerized Prescription Drug Monitoring Program 
(PDMP) (North Dakota Board of Pharmacy, 2012). This monitoring program is designed for 
prescribers, their delegates who are generally licensed nurses, and pharmacists to use and gain 
information on prescription drug filling habits for their patients’ population. 
The PDMP is an agency sponsored by state board of pharmacies, which has a website 
that is available for approved prescribers, their approved delegates, and pharmacists to access 
(North Dakota Board of Pharmacy, 2012). The information that this website reveals is: names of 
individuals, names of controlled substances that were prescribed to the individual, the name of 
the prescriber, and the name of the pharmacy where the prescription was filled. The PDMP user 
needs to enter the first and last name of the individual and the birth date in order to access the 
above information. All scheduled II, III, IV, and some V controlled substances are included in 
the PDMP information. As of January 1st, 2007, Tramadol (Ultram) and Carisoprodol (Soma) 
were added to the reported medications in PDMP (North Dakota Board of Pharmacy, 2012). The 
information is entered into the PDMP system by pharmacists at the time the prescriptions are 
filled. 
The North Dakota PDMP, now called PDMP, has access to certain states, such as, West 
Virginia, Idaho, Wisconsin, Colorado, Minnesota, Illinois, South Dakota, New Mexico, 
Delaware, Kansas, Arizona, Michigan, Indiana, Mississippi, Connecticut, and South Carolina 
(http://northdakota.pmpaware.net).  
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In the northwestern North Dakota critical access hospital’s emergency department and 
rural healthcare clinics, providers have access to the PDMP and approved treatment agreements, 
but neither are consistently used by all providers for every patient that receives pain 
management. Providers also lack a centralized system that monitors patients who seek and 
regularly receive prescriptions for controlled substances.  
 In addition to more frequent use of the PDMP, providers also want to limit the use of 
potentially addictive substances. The duration of pain is important to consider in order to classify 
the pain as acute or chronic. Educating providers to use this stepwise approach of prescribing 
pain medications helped to decrease addiction potential in patients. 
Acute Pain Management Protocols 
 There was a prospective study conducted in Seoul, South Korea at Hangang Sacred Heart 
Hospital burn center from May 2011 through November 2011 regarding general pain 
management and procedural pain management with dressing changes on a population of 107 
burn patients (Yang, Hur, Kwak, Yim, Cho, et al., 2013). The researchers developed a 
comprehensive pain management protocol including several different scales to assess pain, 
anxiety, depression, and post-traumatic stress disorder (Yang et al., 2013). The “numeric rating 
score” (0-10) was used to assess pain as well as several other scales; such as “a Clinician-
Administered Post-traumatic stress disorder Scale (CAPS), a Hamilton Depression Rating Scale 
(HDRS), a State-Trait Anxiety Inventory Scale (STAIS), and a Holmes and Rahe Stress Scale 
(HRSS)” (p. 620). This pain management protocol in this study was used by the staff 
consistently with their patients during each assessment and revised the plan of care based on the 
pain management protocol and changes in the patient’s condition with good results (Yang et al., 
2013).  
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 There was another study conducted in Australia by Miller, Rodger, Kipping, and Kimble 
in 2011 regarding a pain management protocol that was used on children with burns. This 
protocol involved pharmacological and non-pharmacological methods (Miller et al., 2011). The 
pharmacological agents that were used for pain management were paracetamol (known as 
acetaminophen in the United States), Pain Stop (analgesic ointment), and oxycodone (Miller et 
al., 2011). The non-pharmacological methods that were used for pain management was a “Multi-
Modal Distraction (MMD)” device that provides distraction and preparation for a burn wound 
dressing change (Miller et al., 2011). There were three different MMDs that the children could 
choose from, which were: “MMD touch and find stories, MMD games, or the MMD Bobby got a 
Burn story” (p. 398). The MMD use involved one group of study participants. The other group of 
study participants did not have access to the MMDs, but did have access to “television, video 
games, stories, age appropriate toys, nursing staff soothing, and caregiver support throughout the 
change of dressing” (pp. 397-398). Pain assessments were conducted before the dressing change, 
during the removal of the dressing, during the application of the new dressing, and after the 
dressing change (Miller et al., 2011). The result of the study was that the MMD group displayed 
less pain than the “Standard Distraction (SD)” group because the MMD group was given specific 
information on burns and the SD group was given generalized distractions. The MMD group was 
better prepared for the burn dressing change because they were given specific information about 
the upcoming procedure. 
 Another protocol study was conducted in Shiraz, Iran by Mansouri et al. (2013) within a 
nine-month period of time in an Intensive Care Unit (ICU) setting. The authors wanted to 
improve patient outcomes by improving treatment of “pain, agitation, and delirium (PAD)” by 
developing a protocol for the nursing staff to assess and treat the patient as necessary (p. 918). 
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The ICU patients who participated in the study were separated into two groups: the PAD group 
and control group (Mansouri et al., 2013). The PAD group was assessed by the nursing staff 
using the following protocols: “Behavioural Pain Scale (BPS) or Numerical Rating Scale (NRS) 
when feasible, Richmond Agitation Sedation Scale (RASS), and Confusion Assessment Method 
in ICU (CAM-ICU)” (p. 919). The ICU nurses assessed every patient in the PAD group every 
hour for pain, agitation, and delirium according to these scales, and then medicated according to 
the score (Mansouri et al., 2013). Within both the PAD and control groups, the specific 
medications that were given for pain were morphine, fentanyl, sufentanyl, and acetaminophen 
(Mansouri et al., 2013). The medications that were given for agitation were midazolam, propofol, 
and haloperidol (Mansouri et al., 2013). Haloperidol alone was also given for delirium (Mansouri 
et al., 2013). The difference between the PAD and control groups was the method used to assess 
the patients. The authors concluded that implementation of a “well-designed protocol that 
involves regular and precise monitoring of PAD, along with appropriate and timely medical 
therapy” can greatly improve ICU patient outcomes (p. 921).   
Chronic Pain Management Protocols 
 In addition to acute pain management protocols as discussed above, there are a few 
chronic pain management protocols that are found in the literature. Kroenke et al. (2014) 
conducted a study called “The Stepped Care to Optimize Pain Care Effectiveness (SCOPE) (p. 
240). This was a randomized clinical trial that selected veterans from five different primary care 
clinics within the Veterans Administration (VA). These randomly selected participants were 
divided into two groups: one group received pain management via “telephone-delivered 
collaborative care management intervention” and another group which received face-to-face 
office pain management visits with a provider (Kroenke et al., 2014, p. 240). The criteria for the 
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selected participants were that they had to be from 18 to 65 years old; have generalized 
musculoskeletal pain that rated a 5 or above on a 0 to 10 scale; and the participants have had this 
pain at a minimum of three months or greater (Kroenke et al., 2014).  
 In the telecare group, the participants communicated their symptoms via an “automated 
symptom monitoring (ASM)” using their choice of telephone or internet (p. 242). The 
participants utilized the ASM on a scheduled time-frame within twelve months, while using a 
measuring tool designed for the participant’s pain assessment, existence of anxiety or depression, 
and quality of life (Kroenke et al., 2014). Based on the participant’s response; the pain 
management specialist, the primary care provider, and the nurse would create an individualized 
care plan for the participant to receive medication, physical therapy, or cognitive behavioral 
therapy (Kroenke et al., 2014). The nurse would make follow-up calls to verify the participant’s 
automated response. The researchers concluded that the telecare group pain management 
“substantially increased the proportion of primary care patients with improved chronic 
musculoskeletal pain” (p. 247). This study illustrates the importance of frequent follow up with 
patients with chronic pain in order to monitor for potentially worsening co-occurring disorders. 
 There was another study conducted in 2007 by Gallagher, Weiz-Bosna, and Gammaitoni 
at the Pain Medicine Service at Philadelphia Veterans Administration (VA) Medical Center. The 
study prospectively assessed the frequency of “long-acting opioids” in patients with chronic non-
cancer pain. The long-acting opioids that were used in the study were Oxycodone CR, Morphine 
CR, Methadone, and Fentanyl patches (Gallagher et al., 2007). The results of this study were that 
the patients were requiring more frequent dosing of the long-acting opioids that were 
“recommended by the manufacturer” (p. 72). 
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 There was a literature review study conducted by Courtenay and Carey in 2008 in the 
United Kingdom regarding nurses leading in acute and chronic pain management. In the 
beginning of the article, the authors defined acute pain as occurring immediately after surgery, 
traumatic injuries, or life-threatening medical diagnoses such as cardiac arrests. They defined 
chronic pain as pain lasting greater than three months. The authors discovered that nurse-led 
chronic pain management services provide great educational opportunities for patients who 
suffer from chronic pain by using pain management protocols that include “non-pharmacological 
treatments”, such as cognitive behavioral therapy and multiple pain assessment tools (p. 2010). 
These pain specialist nurses can also provide pain management education to other nurses to 
better assess their patients’ pain through pain assessment tools; provide timely implementation of 
pain management, whether pharmacological or non-pharmacological; and improve on evaluation 
of their patients’ pain relief (Courtenay & Carey, 2008). The pain specialist nurses can be in an 
inpatient or outpatient setting. Nurses can be instrumental in pain management assistance and 
education for their patients, which emphasizes the importance of including education for the 
patient.  
 In 2012, the American Pain Society (APS) and the American Academy of Pain Medicine 
(AAPM) created The Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Non 
Cancer Pain. These guidelines recommended several different items for prescribers to adhere to 
regarding management of opioids in their patients; such as, 
 A good history of the patient’s origin and source of pain. 
 Any history of illicit drug or inappropriate prescription drug abuse as well as alcohol 
abuse. 
 Mutual goals and responsibilities between prescriber and patient. 
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 Requirements from the provider that the patient participate in non-pharmacological 
treatment modalities for pain. 
 Written treatment agreement that includes strict guidelines for receiving all prescriptions 
exclusively from the prescriber. 
 The patient filling all prescriptions from one pharmacy. 
 Urine toxicology tests as determined by the prescriber. 
 Guidelines for treatment from the prescriber regarding refill policy and policies for 
office visits (APS & AAPM, 2012). 
Methods of Prescription Drug Abuse Prevention 
In addition to pain management protocols to help prevent prescription drug abuse, Casty, 
Wieman, and Shusterman (2013), discuss in their article, “Current Topics in Opioid Therapy for 
Pain Management: Addressing the Problem of Abuse”, several methods of preventing 
prescription drug abuse. The United States Food and Drug Administration (FDA) have requested 
pharmaceutical companies to add ingredients into opioids that make the drug inactive if it is 
taken in any other form than swallowed whole, such as crushed and snorted or injected (Casty et 
al., 2013). As a result, in the past five years the pharmaceutical companies have altered the 
delivery mechanism of an opioid to become inactive if the drug is taken in any other route other 
than the appropriate route that the drug was therapeutically designed (Casty et al., 2013). 
In addition to the pharmaceutical companies changing their composition of their opioids to 
prevent prescription drug abuse, the FDA determined that the providers who were prescribing 
opioids to their patients need to monitor them frequently. According to Casty et al. (2013), the 
FDA also instituted requirements for pharmaceutical companies to develop a task force called 
“Risk Evaluation and Mitigation Strategies (REMS)”. Within the REMS, there was another task 
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force called “Elements to Assure Safe Use (ETASU)”. The ETASU contains several items that 
require providers to have a certain amount of continuing education in safe opioid prescribing, 
patient monitoring, and frequent patient follow-up visits (Casty et al., 2013). The REMS also 
requires certain protocols to be in place within a healthcare setting in order to maintain safety 
with opioids (Casty et al., 2013). 
Pain Treatment Contracts 
Pain treatment contracts, or treatment agreements, are legal documents that indicate 
important components between a provider and a patient. The information that is included in a 
pain treatment contract may differ in between clinics, but it indicates responsibilities of the 
provider and the patient and consequences that may occur if the responsibility is not followed. 
Pain treatment contracts are generally used in an outpatient clinic setting. 
Hariharan, Lamb, and Neuner published a “retrospective cohort study” in 2007 regarding 
medication treatment contracts for opioid use in a primary care setting (p. 485). The authors 
emphasized the importance of a thorough, methodical, and careful approach with primary care 
providers prescribing opioids to their patients with chronic pain. During this study, there were 
330 patients who agreed to receive opioid prescriptions while using a treatment contract with 
their providers (Hariharan et al., 2007). Within the treatment contract, patients agreed to adhere 
to medication compliance and submitting to random urine drug screens (Hariharan et al., 2007). 
The results of the study include that of the 330 patients, 37% of the contracts were cancelled by 
the end of the study by either the patient or by the provider for presence of illegal drugs in the 
urine drug screen (Hariharan et al., 2007). The authors concluded that medication treatment 
contracts provide “structure, support, and monitoring for long-term chronic pain management” 
(p. 490). 
 23 
 
Arnold, Han, and Seltzer (2006) discuss the usefulness of opioid contracts and the ethical 
dilemmas that can result from their use. They also discuss important objectives that should be 
included in opioid contracts. First, the primary objective of an opioid contract is to establish 
patient compliance within opioid treatment (Arnold et al., 2006).  
Another objective that the authors discuss is the concept of “informed consent” within the 
opioid contract. Arnold et al. (2006) advise to use caution when the provider uses the opioid 
contract as a means of informed consent because all of the components of an informed consent 
must be present; such as “known risks, benefits, and alternatives of opioid therapy” (p. 293). 
Including patient education in the pain management protocol in this project could yield a more 
positive outcome. In order for an opioid contract to be legally sound as an informed consent, it 
must include all components of pain management medical standards (Arnold et al., 2006). The 
wording of such a document must be concise in order to be legal and not put the provider at risk 
for malpractice. 
A third objective identified by the authors is “legal risk management”. They stress the 
importance of spelling out the advantages and disadvantages of opioid therapy. In addition, 
specific goals and expectations of the provider and patient therapeutic relationship must be 
explained thoroughly within the opioid contract (Arnold et al., 2006). The provider should make 
clear what the consequences are if the patient is noncompliant with the requirements of the 
opioid contract.  
The last objective that is discussed is that of “practice efficiency” (p. 294). The authors 
describe the opioid contract as a point of reference for the clinic’s pain management (Arnold et 
al., 2006). The contract can serve as a focus point for the patient’s interdisciplinary care (Arnold 
et al., 2006).  
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The authors also bring up two different viewpoints on opioid contracts. First, the opioid 
contract can be viewed as a positive part of opioid therapy because it is goal-oriented and 
establishes a therapeutic relationship between the patient and the provider. On the other hand, the 
opioid contract can be construed as just a risk management legal document for the provider’s 
benefit and display a “lack of trust” in the patient. To avoid making the opioid contract a 
negative part of opioid therapy, the provider must word the contract carefully and avoid any 
personal biases and remain nonjudgmental (Arnold et al., 2006). The purpose of an opioid 
contract is to establish a therapeutic partnership on the patient’s behalf as well as hold the patient 
accountable for their responsibility of prescribed opioid use. 
Prescription Drug Urine Screening 
 Random urine drug screening that is used on patients can be an effective method that 
providers can use to monitor patients that are being prescribed opioids for pain management. 
Pergolizzi et al. (2010) identified in their article, “The Role of Urine Drug Testing for Patients on 
Opioid Therapy”, two different indications for random urine drug screening. The practice is 
intended to monitor patient compliance with taking the prescribed opioid as well as to monitor 
for any evidence of illicit drug use or using a medication that the provider has not been made 
aware of by the patient. The authors of this article mention that even though most providers 
agree that urine drug screening is an effective method of patient monitoring, it is not ordered by 
providers often. They also comment that, “in one study, only 8% of chronic pain patients on 
opioid therapy ever had a urine drug test administered in this context” (p. 498). Even though 
urine drug screening is considered optional at this time, some states are trying to pass laws 
making it mandatory. The authors state that Florida made urine drug screening mandatory “at 
initial prescription and twice yearly thereafter and medical records that document appropriate 
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testing, treatment plans, informed consent, and periodic review of therapeutic objectives” (p. 
498). 
 Unfortunately, there can be false negatives or false positives in urine drug screens. The 
immunoassay drug screens have certain cutoff levels and if the urine contains levels of the drug 
below the cutoff level, a negative reading is registered (Pergolizzi et al., 2010). False positive 
results can be caused by “cross-reactivity” from one form of opioid to another, for example 
codeine and morphine both display positive results because codeine is metabolized to morphine 
in the liver (Pergolizzi et al., 2010). If there is any doubt of the result, the provider may request 
that the local laboratory send the urine sample to a larger laboratory that can perform a 
confirmation test, such as gas chromatography (Pergolizzi et al., 2010). The authors advise that a 
provider should not make a final conclusion of opioid abuse based on one urine drug screen 
result until further testing is conducted using more sophisticated methods. Urine drug screening 
is a small, but important part of patient prescription drug monitoring. 
Theoretical Framework 
 Within this project, the foundational theory was the Plan, Do, Study, and Act (PDSA) 
model. The PDSA model is important for the project in that it is congruent to the algorithm (see 
Appendix A) in that both are cyclical or ongoing. Within the PDSA model, there are specific 
actions that occur with each phase, such as planning, implementation, evaluation, and 
continuance of the protocol after the project has been completed. 
Plan Do Study Act Model 
 The design of this project was utilized through the PDSA quality improvement model. It 
was derived from the plan, do, check, act (PDCA) that was first developed by Demming and 
Shewhart during World War II (Zaccagnini & White, 2014). This model is important to use in 
 26 
 
system today and, according to, Zaccagnini & White (2014), the PDSA model is used for “rapid 
cycle improvement processes”. The PDSA quality improvement model can be used for a variety 
of healthcare issues that need to be researched and new evidence-based protocols developed in a 
quick and efficient manner, such as in errors in patient identification in computed tomography 
(CT) scans (Barnosky, 2014). This model was helpful in this project in that each phase (plan, do, 
study, act) is included in this model. 
 The first step of the PDSA process is to gather data from the needs assessment and create 
a plan to initiate change in current methods or protocols related to the problem in the healthcare 
system (Ragsdale & Mueller, 2005). All of the prescribers and the administrators of the clinics 
and hospital were interviewed individually by this student, and the common result of each 
interview is that there is a need for established guidelines for pain management in the form of a 
protocol. Providers also felt that consistent use of North Dakota PDMP by either the prescriber 
or a delegated user, such as the nursing staff is necessary. PDMP should be used with each 
opioid prescription. In order to use PDMP, the provider or delegate needs to look up the patient’s 
number and type of controlled substance prescriptions, how many providers that this patient has 
seen in a certain length of time, and how many pharmacies the patient has had prescriptions 
filled. 
 With the prescription drug abuse project, the research participants, or respondents, 
consisted of the prescribers in the northwestern North Dakota clinics and critical access 
hospital’s emergency department. The plan included an extensive review of literature to aid in 
the creation of an evidence-based pain management protocol. The protocol provided consistent 
management strategies for patients that are managed for chronic pain that are treated with highly 
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addictive substances, such as opioids; and medications that are controlled by the Drug 
Enforcement Agency (DEA). 
 The second step, or “do” step, involved creating a protocol to treat acute and chronic 
pain, and incorporated strategies to prevent prescription drug abuse. Some of these strategies 
involved utilization of the prescription drug monitoring program and the initiation of a treatment 
agreement with each patient as appropriate. Providers were asked to provide feedback as the 
protocol is being developed. Once it has been approved by providers and administrators, a 
clinical staff meeting was held to introduce the new protocol to the nursing staff and the support 
staff, and give them a chance to ask questions about the protocol and give feedback. 
 The third step, or “study” step, involved gathering and analyzing data from the pre- and 
post-implementation surveys that were administered to the providers. The data gathered from 
these surveys were reviewed and conclusions were made on whether a pain management 
protocol is effective for prescription drug abuse prevention or not. 
 The fourth step, or “act” step, involved making the new pain management protocol part 
of the standard medical practice in the clinic. After the project was completed with the 
appropriate conclusions met, the research was shared with the stakeholders, which were 
identified as the prescribers in the clinic, the hospital and clinic’s board of directors, hospital 
administrators, which are the chief executive officer and the chief financial officer, and the North 
Dakota Board of Pharmacy. Recommendations for changes were made based upon the results of 
the pre- and post-implementation surveys (see Figure 1). 
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Figure 1. Plan, Do, Study, Act Model 
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CHAPTER THREE. PROJECT DESIGN 
 This project was designed within a critical access hospital’s emergency department and 
two rural health clinics located in northwestern North Dakota. The stakeholders of this project 
included four administrators and nine providers. The project was a case series design because it 
involved the administrators’ and providers’ interpretations of the pain management protocol 
before and after it was implemented (Sullivan, 2012). Each administrator evaluated the effect of 
the protocol on the daily operations within the hospital and clinics. Each provider evaluated the 
effect of the protocol within each of their individual patients with pain management needs. There 
were no control or experimental patient groups. 
Project Implementation 
 In late August of 2015, pre-implementation surveys were distributed to each participating 
administrator and provider. At the time each provider was approached with the surveys, 
education was provided about the study, signs and symptoms of patients with prescription drug 
abuse issues, and education about opioid prescribing best practices, including treatment 
agreements for patients who may have prescription drug abuse issues. In addition to the pre-
implementation surveys, each provider was given a cover letter explaining the purpose of the 
project, a pain management protocol checklist, an algorithm of the pain management protocol, 
and assessment tools, including the Patient Health Questionnaire (PHQ-9) and Dr. Lynn 
Webster’s Opioid Risk Assessment Tool. 
After the surveys were returned to this student from the administrators and providers, 
each licensed staff member (registered nurses and licensed practical nurses) within the hospital 
and clinics was approached individually by this student to educate about identifying risk factors 
of prescription drug abuse in patients. All of the licensed staff members were able to describe 
 30 
 
characteristics of patients with prescription drug abuse issues (i.e., asking for early refills, erratic 
behavior, using multiple providers to obtain prescriptions, using multiple pharmacies to fill 
prescriptions, drug withdrawal signs and symptoms such as diaphoresis, elevated pulse and blood 
pressure). 
 After the individualized staff education was completed, each staff member was instructed 
on enrolling as a delegate in the North Dakota Prescription Drug Monitoring Program or PDMP. 
After each delegate received approval by the North Dakota Board of Pharmacy, the pain 
management protocol was implemented.  
NDSU IRB Approval 
 This project was approved by the North Dakota State University (NDSU) Institutional 
Review Board (IRB), under exempt status category number two. Category two includes survey 
procedures only with observance of human behavior by participating administrators and 
providers. Research was not performed directly with human subjects. The identity of the 
participants was kept confidential and each participant was free from risk of civil or criminal 
liability (NDSU IRB exempt protocol form, 2015).  
Data Collection 
 Each of the administrators and providers were interviewed individually by this student in 
order to determine whether the need for a pain management protocol within the critical access 
hospital’s emergency department and the two rural healthcare clinics existed. The outcome from 
these interviews unanimously supported that a pain management protocol was needed. Data were 
collected from a pre-implementation and post-implementation survey from the administrators 
and providers. The surveys were a hybrid of quantitative and qualitative data. The quantitative 
questions were designed in a five-point Likert scale. Examples of the qualitative questions 
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include asking the participant why the question was answered a certain way as well as perceived 
barriers and benefits of the protocol. 
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CHAPTER FOUR. EVALUATION 
 Within this project, there were three specific objectives identified, which are discussed 
below. The quality improvement model for this project is the Plan, Do, Study, Act model. This 
model is a cyclical type of model which includes four phases in order for each objective to be 
measured for evaluation outcomes. 
Objective One 
 Objective one: Develop and implement a pain management protocol in a rural North 
Dakota primary care clinic and critical access hospital’s emergency department. The utilization 
of treatment agreements between prescribers in the northwestern North Dakota rural healthcare 
clinics and prescribing controlled substances were compared before and after the implementation 
of the pain management protocol by a pre-implementation and a post-implementation survey. 
During the pre-implementation survey, questions were asked about the provider’s current level 
of knowledge about prescription drug abuse, assessment of opioid abuse risks in patients, and the 
provider’s anticipated feelings of benefits or barriers of implementing a pain management 
protocol. During the post-implementation survey, questions were asked about how the provider 
expresses concern to the patient if any signs of prescription drug abuse are being exhibited, how 
often the provider is using the PMDP, and what are the benefits or barriers of the implemented 
protocol. 
Objective Two 
Objective two: Improve, increase, and expand providers’ knowledge about safe opioid 
prescribing practices in order to improve patient monitoring for those receiving opioid therapy 
for chronic pain management. This objective was evaluated by this student conducting a post-
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implementation follow-up survey with all prescribers and administrators within the rural 
healthcare clinics and the critical access hospital’s emergency department.  
Objective Three 
Objective three: Promote utilization and sustainability of the pain management protocol 
through integration of the protocol into daily provider and staff operations in selected clinics 
within four months from project implementation to evaluation. This objective was originally to 
be evaluated by the successful incorporation of the protocol within the electronic medical record. 
Due to the high cost, incorporation of the protocol into the electronic medical records was not 
approved by administration. Instead, a method was incorporated into the daily patient care 
operation by providers and staff within the selected hospital and clinics. This method was created 
by instructing all registered nurses and licensed practical nurses to access the PDMP as 
delegates. When their access was approved by the North Dakota Board of Pharmacy, the nurses 
used the PDMP to research all patients that were prescribed opioids. The report from the PDMP 
was printed out by the nurses and the report was placed on the chart for the provider to review 
before the patient was seen. In addition to available reports for patients being seen, the nurses 
printed out a PDMP report for all patients requesting refills for their opioids.  
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CHAPTER FIVE. RESULTS 
Presentation of Findings 
 A key informant interview was conducted with each project participant to determine each 
individual’s perception of how their patient’s pain is managed effectively. The providers that 
were interviewed agree that the lack of a facility-wide protocol led to prescribing differences of 
medications with potential for abuse. While all providers have knowledge of the PDMP system, 
many acknowledged that the PDMP, which is the best place to search, is not searched each and 
every time an opioid is prescribed. 
 After receiving approval from the IRB, pre-implementation surveys from four 
administrators and seven health care providers were completed. Licensed personnel (RN and 
LPN) were instructed regarding how to create an account with the North Dakota Prescription 
Drug Monitoring Program (PDMP) as a delegate in order to research every patient that presents 
into either the emergency department or either clinic that has an opioid prescription. When each 
licensed staff received approval from the North Dakota Board of Pharmacy as a delegate, the 
protocol went into effect. During the month of November, a post-implementation survey was 
distributed to the study participants, and data from both surveys were analyzed and compared to 
one another.   
Pre-Implementation Surveys for Administrators 
 The questions were in a 5-point Likert scale format developed by this student, with the 
content of the questions assessing the value of implementing the protocol, the anticipated ease of 
implementation of the protocol, the anticipated level of support from the hospital and clinic staff, 
and the anticipated effect of the normal hospital and clinic daily operations by the 
implementation of the protocol (see Table 1 on next page). 
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Table 1  
Administrator Survey Results 
N=4 Pre-Implementation Post-Implementation 
Value for daily operations 3 agree  
1 strongly agree 
3 agree  
1 neither agree or disagree 
Ease of implementation of 
protocol 
2 easy  
2 neutral 
2 easy  
2 neutral 
Level of support from 
hospital and clinical staff 
regarding implementation 
4 somewhat favor 3 somewhat favor 
1 neutral 
Effect of implementation of 
pain management protocol 
with hospital and clinic daily 
operations 
4 somewhat positively 3 somewhat positively 
1 neutral 
 
Post-Implementation Survey Results from Administrators 
 The questions were in a 5-point Likert scale format, with the content of the questions 
being the value of implementing the protocol for daily operations of the organization, the ease of 
implementation of the protocol, the level of support from the hospital and clinic staff, and the 
effect of the normal hospital and clinic daily operations by the implementation of the protocol.  
One administrator from both the hospital and the clinics made the comment that with time, the 
project was successful in deterring prescription drug diversion within the clinic and the hospital 
(see Table 1 above). 
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Pre-Implementation Survey Results from Providers 
 The pre-implementation survey for the providers was a combination of quantitative and 
qualitative data. There was a total of eight pre-implementation surveys returned. The responses 
from the first, second, third, fifth, ninth, and tenth questions are shown in Figure 2 and Table 2. 
Post-Implementation Survey Results from Providers 
 The post-implementation survey for the providers was a combination of quantitative and 
qualitative data. There was a total of eight post-implementation surveys returned. During the 
implementation of the pain management protocol, one medical doctor left the practice and 
dropped out of the project. A nurse practitioner joined the practice approximately midway into 
the project and agreed to participate when approached by this student. There was a total of ten 
questions, which first assessed current level of knowledge regarding best practices for 
prescribing opiates after the pain management protocol was implemented (See Figure 2 and 
Table 2). 
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Figure 2. Provider Survey Results-Mean Values of Responses 
PDMP= Prescription Drug Monitoring Program UDS= Urine Drug Screen 
Legend: 1=not at all aware/never; 2=slightly aware/rarely; 3=somewhat aware/occasionally; 
4=moderately aware/a moderate amount; 5=extremely aware/a great deal 
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Table 2 
Quantitative Data from Provider Surveys 
Question Pre-Implementation (n=8) Post-Implementation (n=8) 
#1 Current level of knowledge 
regarding best practices for 
prescribing opiates. 
8 moderately aware 1 somewhat aware 
4 moderately aware 
3 extremely aware 
#2 Discussing the potential for 
abuse that certain medications 
have with the patient before 
prescribing 
1 sometimes 
5 often 
2 every time 
1 sometimes 
2 often  
5 every time/always 
#3 Discussing concerns with a 
patient if the patient is exhibiting 
signs of prescription drug abuse 
or dependence. 
1 sometimes 
4 often  
5 always 
1 occasionally/sometimes 
1 often/a moderate amount 
5 always 
#5 Current risk assessment of 
opioid abuse prior to prescribing 
chronic opioids to a patient. 
1 rarely 
3 occasionally 
4 a great deal 
1 occasionally 
4 a moderate amount 
3 a great deal 
#9 Pre-implementation/#8 Post-
implementation: How often are 
you using the PDMP? 
1 never 
2 sometimes 
3 often 
2 always 
1 never 
3 occasionally/sometimes 
2 often/almost every time 
1 always/every time 
#10 Pre-implementation/#9 Post-
implementation: How often do 
you use a urine drug screen as 
part of the clinical decision-
making process when prescribing 
controlled substances? 
1 never 
1 almost never 
5 occasionally/sometimes 
1 almost every time 
2 never 
2 occasionally/sometimes 
3 almost every time 
1 every time 
 
#10 Post-implementation: How 
often do you follow the protocol 
when you prescribe a controlled 
substance? 
N/A (n=7) 
1 never 
1 occasionally/sometimes 
4 almost every time 
1 every time 
  
Based on the above findings, this student concluded that the providers’ current level of 
knowledge varied with the post-implementation survey. The providers increased the frequency in 
which they discussed with their patients the potential for abuse that certain medications have 
before they prescribed the medication. The frequency of urine drug screen use changed 
minimally between the pre- and post-implementation surveys. 
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Qualitative Data from Pre-Implementation Provider Survey 
 The fourth question asked the providers about the strategies that they use to promote the 
health of their patient. Their responses were consistent in prioritizing the promotion of safe 
opioid prescribing. One provider responded: “Try not to alienate them or be accusatory but rather 
express concern for their long term general well-being.” 
The majority of the providers responded that they assessed a patient’s risk of opioid 
abuse prior to prescribing chronic opioids by reviewing records and discussion with the patient. 
One provider responded that a “state search” (PDMP) of the patient is important prior to 
prescribing opioids. 
The sixth question was about the providers’ thoughts or feelings about implementation of 
the pain management protocol. The majority of the providers responded favorably about 
implementing a pain management protocol. One individual responded: “It would be nice for a 
clinic that has a variety of providers to have one protocol so that everyone is on the same page. 
That said, there is something nice about provider autonomy as we all practice differently and 
relate differently with certain types of patients.” Most providers expressed interest in having a 
protocol available for guidance while maintaining autonomy. 
The seventh question was about the providers’ anticipation of the benefits of a pain 
management protocol. One individual responded: “Decreases the provider risk with prescribing 
controlled substances. Patient will abuse meds no matter what protocols are in place.” Another 
individual responded: “The protocol should help prevent patients changing providers if unhappy 
since same protocol will be followed by all.” The majority of the providers responded that the 
protocol would be beneficial for both the patient and the provider. 
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The eighth question was about the providers’ anticipation of the barriers of implementing 
a pain management protocol. The majority of the providers expressed concern about the extra 
time and energy that the protocol would require. One individual commented that the protocol 
would affect: “Patient compliance. Risk of negative patient reviews.”  
The ninth and tenth questions about PDMP use and urine drug screen use, respectively, 
are illustrated in Figure 2 and Table 2. One of the providers’ responses for the reasons why they 
do not use the PDMP was as follows: “Retired MD. Do not have my own patients anymore.” 
One of the providers’ responses regarding urine drug screen use was as follows: “Depends on my 
trust of the patient. If they are new I use it, but if they are routinely compliant, I don't use these 
with every visit." Another provider responded: “Inaccuracy of the test. High rate of false 
positives.” 
Qualitative Data from Post-Implementation Provider Surveys 
  The fourth question asks the provider to list strategies that are used to promote the 
health of that patient. One of the providers’ responses was as follows: “I express my concerns 
with the patient. I explain why I am concerned. Monitor the patient more closely with more 
frequent visits, urine drug screens, check prescription drug monitoring program more frequently. 
Refer to pain management and/or addiction medicine.” The majority of the providers’ responses 
were consistent with safe opioid prescribing.  
The fifth question asks if the provider currently assesses risks of opioid abuse prior to 
prescribing chronic opioids to a patient.  This question was a hybrid of quantitative and 
qualitative data. One of the responses as to how they assess risks of opioid abuse prior to 
prescribing chronic opioids to a patient was: “Ask about history of substance abuse. Screen for 
depression.” The rest of the providers had similar responses.  
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The sixth question asks the provider what thoughts or feelings that he/she has about the 
implementation of the pain management protocol. One provider did not answer the question. One 
of the other provider’s responses was: “Neutral. Unchanged. Good theory behind protocol.” 
Another provider responded: “I appreciate the additional education.” The remainder of the 
providers responded that the protocol was helpful to prevent prescription drug abuse.  
The eighth question asks the provider how often he/she uses the Prescription Drug 
Monitoring Program, and if not, why? One provider commented that they only provided “part-
time ER coverage” and did not feel the need to use the PDMP. Another provider commented: 
“Sometimes it’s down or it’s for a few days following an ER visit. Time constraints can be 
inhibiting”. There was a decrease in the frequency in the providers’ use of the PDMP in the post-
implementation survey because of the RN and LPN delegates. 
The ninth question asks the provider how often a urine drug screen was used as part of 
the clinical decision-making process when prescribing controlled substances.  One of the 
providers that answered “never” commented: “Unreliable results. Both false positives and false 
negatives”. One provider commented: “Most affordable urine drug screens not accurate enough 
to use to make decisions about treatment”.    
The eleventh question asks the provider what are the barriers to consistent use of the 
protocol. One of the provider’s answers was: “Increased time required to do things such as drug 
screens and check prescription drug monitoring program.” The majority of the providers were 
concerned about time management and energy spent on the protocol.  
The twelfth question asks what the advantages were with consistent use of the protocol. 
One of the provider’s answers was: “Increased providers’ comfort and ease of use. Uniform 
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patient expectations and care delivery.” The remainder of the providers responded that the 
protocol improved patient care and decreased opioid abuse within the clinic. 
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CHAPTER SIX. DISCUSSION AND RECOMMENDATIONS 
Interpretation of Results 
 Based on these results, the providers were supportive of the pain management protocol 
before and after its implementation. However, the providers continued to practice in their own 
methods. For example, the providers who did not believe urine drug screens were reliable before 
the protocol was implemented still did not believe that urine drug screens were reliable after the 
protocol.  
Objective One 
Objective one: Develop and implement a pain management protocol in a rural 
North Dakota primary care clinic and critical access hospital’s emergency department. Pre-
implementation surveys were distributed to four administrators and nine providers, which all of 
the surveys were returned to this student within two weeks. At the time of survey distribution, 
each administrator and provider was given an explanation of the pain management protocol, with 
a cover letter with an explanation of the research study, a copy of the algorithm, a pain 
management protocol checklist, and assessment tools including a Patient Health Questionnaire 
(PHQ-9) and an Opioid Risk Tool. There were no providers that stated that they used the PHQ-9 
nor the Opioid Risk Tool in their assessment of their patients whom were prescribed opioids. 
 In addition to meeting with administrators and providers, this student met individually 
with each licensed staff member (registered nurses and licensed practical nurses (RN and LPN), 
in the critical access hospital’s emergency department and the rural healthcare clinic. Each RN 
and LPN was taught and instructed to register online with the North Dakota PDMP as a delegate. 
Also, each staff member was educated about recognizing signs of acute withdrawal (i.e., aberrant 
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behavior, asking for early refills, agitation, elevated blood pressure and pulse, and excessive 
perspiration or diaphoresis). 
 The objective was partially achieved. The key facilitators that made the objective 
achievable were full participation from the RNs and LPNs at the rural healthcare clinic. The staff 
at the clinic utilized the PDMP for all patients that presented to the clinic for a pain management 
appointment and for all patients who called requesting an opioid refill. The clinic staff printed 
out a PDF file of each patient’s prescription activity for the past year and had a copy on the 
patient’s chart for the provider to review at the time the patient was seen. Also, a PDF file was 
available to the provider with the opioid refill request. By having these reports available to 
providers, time constraints for informed opioid prescribing were minimal. Also, the PDMP use 
by the providers decreased after the protocol was implemented because the delegates were using 
the PDMP on the providers’ behalf. 
 The key barrier was minimal participation from the critical access hospital’s emergency 
department staff. During the time the pain management protocol was initiated, a new hospital 
electronic medical record system was implemented. This pain management protocol was a lesser 
priority than the becoming proficient with the electronic health record. Extra time was given with 
individual explanation of the protocol to the hospital staff to minimize frustration. There were 
ten RNs in the critical access hospital’s emergency department. All of them received the same 
education about the pain management protocol as the clinic staff. Four out of the ten RNs 
followed through with using the PDMP with each emergency department patient, each acute 
inpatient, and each swing bed patient. The Director of Nursing at the critical access hospital’s 
emergency department remained neutral to the protocol after it was implemented because of the 
higher priority of the new electronic medical record system. 
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Objective Two 
Objective two: Improve, increase, and expand providers’ knowledge about safe 
opioid prescribing practices in order to improve patient monitoring for those receiving 
opioid therapy for chronic pain management. The objective was achieved to a great extent 
due to the providers responding in a similar way in both the pre- and post-implementation 
surveys. The responses, however, were diverse in using urine drug screens. Some providers did 
not feel that the urine drug screen results were reliable enough to make a clinical decision of the 
patient abusing prescription drugs. Others felt that urine drug screens were essential in 
monitoring their patients for prescription drug abuse. 
Many providers stated that they had a strong knowledge base of recognizing signs of 
prescription drug abuse that were displayed by their patients. None of the providers verbalized 
that they used the PHQ-9 or the Opioid Risk Tools during their patient assessments. The key tool 
the providers felt was important was using PDMP in monitoring their patients for prescription 
drug abuse. After the protocol was implemented, a few providers expressed improvement in the 
frequency of assessing their patients for abuse and using urine drug screens in their post-
implementation surveys. There were two providers who did not change their practice in not using 
urine drug screens on their patients because of their unchanged belief that they were unreliable. 
The key barrier identified by the providers and administrators was time constraints in 
using the pain management protocol. The main barrier was taking the time to research the PDMP 
for prescription drug activity. One way to overcome the barrier was to have the staff perform the 
PDMP inquiry for the providers so they could spend time with the patient.  
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Objective Three 
 Objective three: Promote utilization and sustainability of the pain management 
protocol through integration of the protocol into daily provider and staff operations in 
selected clinics within four months from project implementation to evaluation. The 
objective was fully achieved within the rural healthcare clinics, and partially achieved within the 
critical access hospital’s emergency department, mainly due to lack of participation. The key 
facilitators were the cooperation of the nursing staff at both the rural healthcare clinics and the 
critical access hospital’s emergency department participating as delegates for patient research in 
the PDMP and recognizing signs of prescription drug abuse in patients who were abusing 
opioids. Since the protocol was implemented, some providers chose not to prescribe opioids to 
patients. Many providers that participated in the project stated that they did not prescribe opiates 
because of the frequent monitoring and the liability that is involved with safe opiate prescribing. 
The delegates and providers are still using the PDMP. Some of the providers are using urine drug 
screens more frequently since the implementation of the pain management protocol.  
 A key barrier was that the cost of integrating the use of the PDMP into the electronic 
medical records (EMR) was more than the administrators could afford in their budget. The cost 
of the integration of the PDMP use into the EMR that was quoted by the EMR programmers was 
$15,000. The licensed staff were already researching the hard copy charts every afternoon for 
faxed copies of lab or diagnostic imaging reports for the next day’s scheduled patients, so 
researching the PDMP was easily incorporated into their daily research. The licensed staff 
expressed concern about another task with PDMP research, but when they were instructed on 
how to use the PDMP and after they were approved as a delegate by the North Dakota Board of 
 47 
 
Pharmacy, they accepted the new task. The payroll cost of the licensed staff did not change as a 
result of the PDMP search. 
Limitations 
 The main limitation to this project was the time frame in which it was conducted. Four 
months was an adequate time frame for the project, but six to eight months would have been 
better in that more observation could have been conducted by this student with providers’ opioid 
prescribing practices. Another limitation was that the critical access hospital’s emergency 
department and rural healthcare clinics were downsizing by three medical doctors, one doctor of 
osteopathy, and two nurse practitioners. This happened during December of 2015, so this student 
distributed the post-implementation surveys during November of 2015.  
 Another limitation was the electronic medical record upgrade in the critical access 
hospital’s emergency department. The nurse administrator and the staff RNs were so involved 
with the upgrade that they were not able to give their undivided attention to the pain management 
protocol. Additional time was spent with the staff to provide the education and support necessary 
to become PDMP delegates in an effort to improve the success of the PDMP.  
 The integration of the protocol into the electronic medical records would have been 
beneficial to make the protocol more “user-friendly” and sustainable. Many of the providers 
would have forgotten about the protocol had it not been for the nurses researching the PDMP as 
delegates. The cost of integration of the protocol into the electronic medical records was an 
unfortunate barrier.  
Recommendations for Future Research 
 Prescription drug abuse is a problem of a large magnitude in this country that each patient 
should be closely monitored for all signs of abuse and questionable drug activity. The best 
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centralized system for monitoring prescription drug activity in the United States is the 
Prescription Drug Monitoring Program (PDMP). PDMP use has already been strongly 
encouraged in North Dakota as well as many other states.  Providers find their responsibilities 
easier to have delegates to conduct the online research on all patients who are prescribed opioids 
and other controlled substances and to recognize signs of patients who have prescription drug 
abuse issues, which was what this project was all about.  
 The area of the project with the biggest impact and potential for sustainable change in the 
North Dakota project involved improved PDMP utilization. Projects should be initiated within 
clinics and hospitals to enhance PDMP utilization rates in each state. The DEA, who executes 
prescriptive authority to all providers, expects all providers to research their patients in the 
PDMP on a regular basis. There are many electronic medical records that provide a space to 
document that PDMP was checked for the patient.  
Implications for Practice 
 Dissemination of the results of this project was conducted at a local pain management 
center as well as at a coalition meeting for substance abuse prevention, which included providers, 
law enforcement, and the local school system. This student also displayed her poster describing 
her project at the youth network committee meeting.  
 This project was designed to make providers aware of the magnitude of prescription drug 
abuse and improve patient monitoring with a centralized electronic monitoring system. This 
project was not intended to substitute a provider’s clinical judgment. 
 Future research is needed on methods to prevent prescription drug abuse. There is 
widespread awareness in social media and more emphasis for providers to increase patient 
monitoring for those who are prescribed opioids or other controlled substances. It takes all 
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providers to be astute with their close monitoring and communication with their patients to be 
aware of certain medications that have a high potential for abuse. These medications should be 
used as a last resort for effective therapy. 
Application to DNP Roles 
 DNPs can be very effective leaders in initiating pain management protocols within their 
healthcare systems if there is not one already in place. They can advocate for close patient 
monitoring for prescription drug abuse problems and educate other providers to recognize signs 
of aberrant behavior. DNPs can also be great role models and mentors to those providers who 
have knowledge deficits of controlled substance prescribing, as well as those providers who have 
fears of legal consequences if they do prescribe controlled substances.  
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APPENDIX A. PAIN MANAGEMENT PROTOCOL ALGORITHM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient arrives  
with chief  
complaint of pain 
Health Care Provider or designee checks the PDMP. Is there patient  
activity in PDMP? 
Patient will be seen by provider. 
Pain  
Management  
Protocol 
No Yes 
Patient will be  
instructed to follow-up  
with the previous  
provider if in the clinic.  
If patient presents to  
the Emergency Dept,  
limited supply of  
controlled substances  
will be dispensed, if  
needed. 
Is patient in pain? Does patient need prescription for  
pain management? 
Yes 
Gather pain history.  
Obtain previous  
records. Full  
assessment of pain.   
  
 
No 
Provider offers  
physical therapy or  
advises patient to  
use OTC  
medication. 
Chronic pain: 
Consider  
depression  
screening using  
PHQ9 tool.  
Consider adjuncts  
like duloxetine,  
pregabalin, or  
gabapentin in  
addition to or  
instead of opioids 
Consider yoga,  
guided imagery,  
CBT, biofeedback,  
or counseling. 
Yes 
Provider prescribes  
pain medication  
according to the  
severity of the  
patient's pain.  
Use risk tool. 
Need follow-up  
appointment? 
reference: American  
Pain Society &  
American Academy  
of Pain Medicine.  
(2012). 
No 
Need medication? 
No 
Patient leaves 
Yes 
Patient makes an  
appt and provider  
establishes a  
treatment  
agreement. 
Yes 
Rx given to pt and  
teaching pain  
management rules  
via tx agreement. 
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APPENDIX B. INSTITUTIONAL REVIEW BOARD APPROVAL LETTER 
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APPENDIX C. PRE-IMPLEMENTATION ADMINISTRATIVE SURVEY 
Please indicate level of agreement with the following statements.  
1. Implementing the pain management protocol will be valuable for the daily operations of the 
organization. 
a. Strongly disagree 
b. Somewhat Disagree 
c. Neither agree nor disagree 
d. Agree 
e. Strongly agree 
If strongly disagree or somewhat disagree, why? 
2. How do you anticipate the ease of implementation for the pain management protocol? 
a. Very difficult 
b. Difficult 
c. Neutral 
d. Easy 
e. Very easy 
If very difficult or difficult, why? 
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3. What do you anticipate will be the level of support from the hospital and clinic staff regarding 
the implementation of the pain management protocol? 
a. Strongly oppose 
b. Somewhat oppose 
c. Neutral 
d. Somewhat favor 
e. Strongly favor 
4. How do you anticipate the implementation of the pain management protocol will affect normal 
hospital and clinic daily operations? 
a. Very negatively 
b. Somewhat negatively 
c. Neutral 
d. Somewhat positively 
e. Very positively 
If very negatively or somewhat negatively, why? 
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APPENDIX D. POST-IMPLEMENTATION ADMINISTRATIVE SURVEY 
1. Implementing the pain management protocol has been valuable for the daily operations of the 
organization. 
a. Strongly disagree 
b. Somewhat disagree 
c. Neither agree nor disagree 
d. Agree 
e. Strongly agree 
If strongly disagree or somewhat disagree, why? 
2. How do you feel about the ease of implementing the pain management protocol? 
a. Very difficult 
b. Difficult 
c. Neutral 
d. Easy 
e. Very easy 
If very difficult or difficult, why? 
3. What is your perception of the level of support regarding the pain management protocol 
implementation from the hospital and clinic staff? 
a. Strongly oppose 
b. Somewhat oppose 
c. Neutral 
d. Somewhat favor 
e. Strongly favor 
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If strongly oppose or somewhat oppose, why? 
4. How has the implementation of the pain management protocol affected normal hospital and 
clinic daily operations? 
a. Very negatively 
b. Somewhat negatively 
c. Neutral 
d. Somewhat positively 
e. Very positively 
If very negatively or negatively, why? 
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APPENDIX E. PRE-IMPLEMENTATION PROVIDER SURVEY 
1. How would you describe your current level of knowledge regarding best practices for 
prescribing opiates? 
a. Not at all aware 
b. Slightly aware 
c. Somewhat aware 
d. Moderately aware 
e. Extremely aware 
2. Do you discuss the potential for abuse that certain medications have with the patient before 
you prescribe them? 
a. Never 
b. Rarely 
c. Occasionally/Sometimes 
d. Often 
e. Every time 
3. If you are concerned that a patient is exhibiting signs of prescription drug abuse or 
dependence, do you discuss your concerns with the patient? 
a. Never 
b. Rarely 
c. Sometimes 
d. Often 
e. Always 
4. If so, what strategies do you use to promote the health of that patient? 
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5. Do you currently assess risk of opioid abuse prior to prescribing chronic opioids to a patient? 
a. Never 
b. Rarely 
c. Occasionally 
d. A moderate amount 
e. A great deal 
If so, how? 
6. What are your feelings or thoughts about the implementation of the pain management 
protocol? 
7. What do you anticipate will be the benefits of a pain management protocol? 
8. What do you anticipate will be the barriers of implementing a pain management protocol? 
9. How often do you use the Prescription Drug Monitoring Program (PDMP)? 
a. Never 
b. Rarely 
c. Sometimes 
d. Often 
e. Always 
If not, why? 
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10. How often do you use a urine drug screen as part of the clinical decision-making process 
when prescribing controlled substances? 
a. Never 
b. Almost never 
c. Occasionally/Sometimes 
d. Almost every time 
e. Every time 
If not, why? 
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APPENDIX F. POST-IMPLEMENTATION PROVIDER SURVEY 
1. How would you describe your current level of knowledge regarding best practices for 
prescribing opiates since the pain management protocol was implemented? 
a. Not at all aware 
b. Slightly aware 
c. Somewhat aware 
d. Moderately aware 
e. Extremely aware 
2. Do you discuss the potential for abuse that certain medications have with patients before you 
prescribe them? 
a. Never 
b. Rarely 
c. Sometimes 
d. Often 
e. Always 
3. If you are concerned that a patient is exhibiting signs of prescription drug abuse or 
dependence, do you discuss your concern with the patient? 
a. Never 
b. Rarely 
c. Occasionally 
d. A moderate amount 
e. A great deal 
4. If so, what strategies do you use to promote the health of that patient? 
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5. Do you currently assess risk of opioid abuse prior to prescribing chronic opioids to a patient? 
a. Never 
b. Rarely 
c. Occasionally 
d. A moderate amount 
e. A great deal 
If so, how? 
6. What are your feelings or thoughts after the implementation of the pain management protocol? 
7. How would you describe the ease or difficulty of the implementation of the protocol? 
a. Very difficult 
b. Difficult 
c. Neutral 
d. Easy 
e. Very easy 
8. How often are you using the Prescription Drug Monitoring Program (PDMP)? 
a. Never 
b. Almost never 
c. Occasionally/Sometimes 
d. Almost every time 
 e. Every time 
If not, why? 
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9. How often do you use a urine drug screen as part of the clinical decision-making process when 
prescribing controlled substances since the pain management protocol has been 
implemented? 
a. Never 
b. Almost never 
c. Occasionally/Sometimes 
d. Almost every time 
e. Every time 
If not, why? 
10.   How often do you follow the protocol when you prescribe a controlled substance? 
a. Never 
b. Almost never 
c. Occasionally/Sometimes 
d. Almost every time 
e. Every time 
11. What are the barriers to consistent use of the protocol? 
12. What are the advantages to consistent use of the protocol? 
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APPENDIX G. EXECUTIVE SUMMARY 
Prescription drug abuse is an intentional misuse of a prescribed drug for recreational or 
other purposes that was not intended by the prescriber of the drug. Since 2012, fatalities from 
opioid overdoses have risen to approximately 17,000 per year in the United States. The clinical 
dissertation project was about prescription drug abuse and how to deter it by developing and 
implementing an evidence-based pain management protocol. This student worked at a rural 
health clinic and a critical access hospital’s emergency department in northwestern North Dakota 
that did not have a standard protocol to manage acute or chronic pain. This purpose of this 
project was to bring about awareness on how to deter or prevent prescription drug abuse and to 
develop a standardized protocol within the critical access hospital’s emergency department and 
rural health clinic in order to bring about solutions to the above problems. 
Background 
 There were many transient oil workers and families that were patients at the rural health 
clinic and at the critical access hospital’s emergency department in northwestern North Dakota. 
Many of these patients had issues with acute or chronic pain and since they were only in the area 
temporarily, they were receiving prescriptions from different providers in different states, thus 
creating a problem within the health care system. This student was advised by the administrators 
to refer the patients to pain management specialist in two different cities which were at least one 
hundred miles away. After the patients would go to the pain management specialist, they would 
be referred back to primary care to manage their pain. This would create more expense and 
inconvenience for the patient. 
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 When this student was preparing for research, she discussed the need for a pain 
management protocol with each administrator and provider individually. It was unanimous that a 
pain management protocol was needed, so this student developed her project.  
 The parties involved included the North Dakota Board of Pharmacy and the 
administrators, providers, and nurses of the rural health clinic and critical access hospital’s 
emergency department in northwestern North Dakota. The research process included institutional 
review board (IRB) approval from North Dakota State University as exempt status because 
humans were not directly involved in the research. After IRB approval was obtained, this student 
distributed pre-implementation surveys to each administrator and provider. This student provided 
individual instruction to each registered nurse and licensed practical nurse on what to look for 
during their assessment of a patient experiencing opioid withdrawal. Instructions were provided 
to each nurse on how to apply as a delegate on the North Dakota Prescription Drug Monitoring 
Program (PDMP). As a delegate, the nurses would research each patient that presented with pain 
symptoms, requesting controlled substance refills, or would come into the clinic or hospital for a 
pain management follow-up visit. 
 Education was given to providers about best practices regarding opioid prescribing. 
Providers were educated about the importance of PDMP research to know their patient’s 
prescription drug activity before prescribing any medication to them. Providers were also 
educated about frequent monitoring of their patients to whom they prescribe opioids, including 
treatment contracts, pill counts, and urine drug screens. 
 The protocol was implemented for four months and did show improvement in monitoring 
for prescription drug abuse. After four months, a post-implementation survey was distributed to 
each administrator and provider.  
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Findings and Conclusions 
 The major findings are that the administrators answered in their surveys that the protocol 
improved the daily operations of the clinic. The providers answered in their surveys that it was 
helpful that the nurses were delegates in order to save the providers’ time so that they could 
focus on the patient. Providers became more aware of the prescription drug abuse problem and 
were more cognizant of any of their patients’ aberrant behaviors.  
There were some confounding variables that affected the critical access hospital’s 
emergency department results, however. There was a new version of the electronic medical 
record that was being installed and the director of nursing and the staff nurses prioritized 
learning the new HER rather than becoming a delegate in PDMP. Another confounding variable 
was that the transient population declined due to the local economy declining. Virtually all of the 
local oil wells closed and this student’s employment contract was shortened as a result of the 
declining economy. 
 The providers did become more aware of their controlled substance prescribing practices 
as a result of the research. The research did improve patient safety of pain management by 
improving knowledge and awareness to the administrators and providers to use opioids as a last 
resort to treat pain and to use other modalities such as physical therapy.  
 The providers benefitted from the research because they were encouraged from the 
North Dakota Board of Pharmacy to use PDMP themselves or have a delegate. It is a new best 
practice for every clinic and hospital in the nation have a pain management protocol in force in 
order to control opioid prescribing practices and monitor patients closely for diversion.  
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Recommendations for Further Action 
In October of 2014 the Drug Enforcement Agency (DEA) moved hydrocodone up from a 
Schedule III controlled substance to a Schedule II controlled substance, which limited 
prescribing to a quantity of a one-month supply and no refills. According to Kathy Zahn, the 
director of PDMP, the North Dakota Board of Pharmacy has already begun monitoring each 
provider’s use of PDMP and if a provider is found not to be using the database, their licensing 
organizations will be notified for possible further disciplinary action. 
  
 
 
 
 
 
 
 
 
 
 
